339 related articles for article (PubMed ID: 23144808)
21. Prolonged therapy with the soluble guanylyl cyclase activator BAY 60-2770 restores the erectile function in obese mice.
Silva FH; Leiria LO; Alexandre EC; Davel AP; Mónica FZ; De Nucci G; Antunes E
J Sex Med; 2014 Nov; 11(11):2661-70. PubMed ID: 25196910
[TBL] [Abstract][Full Text] [Related]
22. Different influences of extracellular and intracellular superoxide on relaxation through the NO/sGC/cGMP pathway in isolated rat iliac arteries.
Tawa M; Shimosato T; Iwasaki H; Imamura T; Okamura T
J Cardiovasc Pharmacol; 2015 Feb; 65(2):160-7. PubMed ID: 25329747
[TBL] [Abstract][Full Text] [Related]
23. Aged Garlic Extract Inhibits Human Platelet Aggregation by Altering Intracellular Signaling and Platelet Shape Change.
Rahman K; Lowe GM; Smith S
J Nutr; 2016 Feb; 146(2):410S-415S. PubMed ID: 26764324
[TBL] [Abstract][Full Text] [Related]
24. Soluble guanylyl cyclase activation with HMR1766 attenuates platelet activation in diabetic rats.
Schäfer A; Flierl U; Kobsar A; Eigenthaler M; Ertl G; Bauersachs J
Arterioscler Thromb Vasc Biol; 2006 Dec; 26(12):2813-8. PubMed ID: 17023677
[TBL] [Abstract][Full Text] [Related]
25. Activation of soluble guanylyl cyclase with inhibition of multidrug resistance protein inhibitor-4 (MRP4) as a new antiplatelet therapy.
Mendes-Silverio CB; Lescano CH; Zaminelli T; Sollon C; Anhê GF; Antunes E; Mónica FZ
Biochem Pharmacol; 2018 Jun; 152():165-173. PubMed ID: 29605625
[TBL] [Abstract][Full Text] [Related]
26. The fibrate gemfibrozil is a NO- and haem-independent activator of soluble guanylyl cyclase: in vitro studies.
Sharina IG; Sobolevsky M; Papakyriakou A; Rukoyatkina N; Spyroulias GA; Gambaryan S; Martin E
Br J Pharmacol; 2015 May; 172(9):2316-29. PubMed ID: 25536881
[TBL] [Abstract][Full Text] [Related]
27. Effect of soluble guanylyl cyclase activator and stimulator therapy on nitroglycerin-induced nitrate tolerance in rats.
Jabs A; Oelze M; Mikhed Y; Stamm P; Kröller-Schön S; Welschof P; Jansen T; Hausding M; Kopp M; Steven S; Schulz E; Stasch JP; Münzel T; Daiber A
Vascul Pharmacol; 2015 Aug; 71():181-91. PubMed ID: 25869522
[TBL] [Abstract][Full Text] [Related]
28. The sGC activator BAY 60-2770 has potent erectile activity in the rat.
Lasker GF; Pankey EA; Frink TJ; Zeitzer JR; Walter KA; Kadowitz PJ
Am J Physiol Heart Circ Physiol; 2013 Jun; 304(12):H1670-9. PubMed ID: 23585129
[TBL] [Abstract][Full Text] [Related]
29. Antiplatelet properties of a novel, non-NO-based soluble guanylate cyclase activator, BAY 41-2272.
Hobbs AJ; Moncada S
Vascul Pharmacol; 2003 Oct; 40(3):149-54. PubMed ID: 13678646
[TBL] [Abstract][Full Text] [Related]
30. Analysis of nitric oxide-sensitive guanylyl cyclase in human platelets before and after aggregation.
Kempfert J; Behrends S
Platelets; 2003; 14(7-8):429-35. PubMed ID: 14713512
[TBL] [Abstract][Full Text] [Related]
31. Acrylamide analog as a novel nitric oxide-independent soluble guanylyl cyclase activator.
Nakane M; Kolasa T; Chang R; Miller LN; Moreland RB; Brioni JD
J Pharmacol Sci; 2006 Oct; 102(2):231-8. PubMed ID: 17050951
[TBL] [Abstract][Full Text] [Related]
32. Thrombospondin-1 is an inhibitor of pharmacological activation of soluble guanylate cyclase.
Miller TW; Isenberg JS; Roberts DD
Br J Pharmacol; 2010 Apr; 159(7):1542-7. PubMed ID: 20233213
[TBL] [Abstract][Full Text] [Related]
33. Biphasic roles for soluble guanylyl cyclase (sGC) in platelet activation.
Zhang G; Xiang B; Dong A; Skoda RC; Daugherty A; Smyth SS; Du X; Li Z
Blood; 2011 Sep; 118(13):3670-9. PubMed ID: 21803853
[TBL] [Abstract][Full Text] [Related]
34. Pulmonary and systemic vasodilator responses to the soluble guanylyl cyclase activator, BAY 60-2770, are not dependent on endogenous nitric oxide or reduced heme.
Pankey EA; Bhartiya M; Badejo AM; Haider U; Stasch JP; Murthy SN; Nossaman BD; Kadowitz PJ
Am J Physiol Heart Circ Physiol; 2011 Mar; 300(3):H792-802. PubMed ID: 21217076
[TBL] [Abstract][Full Text] [Related]
35. NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle.
Stasch JP; Schmidt P; Alonso-Alija C; Apeler H; Dembowsky K; Haerter M; Heil M; Minuth T; Perzborn E; Pleiss U; Schramm M; Schroeder W; Schröder H; Stahl E; Steinke W; Wunder F
Br J Pharmacol; 2002 Jul; 136(5):773-83. PubMed ID: 12086987
[TBL] [Abstract][Full Text] [Related]
36. A novel soluble guanylyl cyclase activator, BR 11257, acts as a non-stabilising partial agonist of sGC.
Elgert C; Rühle A; Sandner P; Behrends S
Biochem Pharmacol; 2019 May; 163():142-153. PubMed ID: 30753814
[TBL] [Abstract][Full Text] [Related]
37. Chronological Change of Vascular Reactivity to cGMP Generators in the Balloon-Injured Rat Carotid Artery.
Tawa M; Shimosato T; Sakonjo H; Masuoka T; Nishio M; Ishibashi T; Okamura T
J Vasc Res; 2019; 56(3):109-116. PubMed ID: 31085923
[TBL] [Abstract][Full Text] [Related]
38. BAY 60-2770 activates two isoforms of nitric oxide sensitive guanylyl cyclase: Evidence for stable insertion of activator drugs.
Sömmer A; Sandner P; Behrends S
Biochem Pharmacol; 2018 Jan; 147():10-20. PubMed ID: 29155144
[TBL] [Abstract][Full Text] [Related]
39. The soluble guanylate cyclase stimulator riociguat and the soluble guanylate cyclase activator cinaciguat exert no direct effects on contractility and relaxation of cardiac myocytes from normal rats.
Reinke Y; Gross S; Eckerle LG; Hertrich I; Busch M; Busch R; Riad A; Rauch BH; Stasch JP; Dörr M; Felix SB
Eur J Pharmacol; 2015 Nov; 767():1-9. PubMed ID: 26407652
[TBL] [Abstract][Full Text] [Related]
40. Soluble guanylyl cyclase activator YC-1 inhibits human neutrophil functions through a cGMP-independent but cAMP-dependent pathway.
Hwang TL; Hung HW; Kao SH; Teng CM; Wu CC; Cheng SJ
Mol Pharmacol; 2003 Dec; 64(6):1419-27. PubMed ID: 14645672
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
